Predictive Toxicology: Stem Cell Characterisation Must Mature

Add bookmark
In line with this year’s Predictive Toxicology Academy, Pharma IQ held an exclusive interview with Phillip Hewitt, Head of Early Investigative Toxicology at Merck KGaA to find out his thoughts on the new innovations within predictive toxicology and the vital improvements needed to the application of Induced Pluripotent Stem Cells (iPSCs) in drug discovery today. Pharma IQ: Give us a flavour of your work within predictive toxicology and a few trends you are noticing in the market? Philip: &n...

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended